Our Board of Directors
Andrew Hall is Founder of Black Tulip Group, an advisory and investment firm focused on the marketing, media and information services industries. Prior to forming Black Tulip, Andrew served as Executive Vice President of WPP Group plc, the world’s largest advertising and marketing services company, where he worked from 1993-2000. During this period, WPP enjoyed great success as a consolidator of the industry growing from around $2 billion in revenue to around $7 billion and being amongst the very best performing companies in the FTSE 100. Prior to joining WPP, Andrew worked in the UK with both Arthur Andersen & Co. and the Corporate Advisory Services Group of Ernst & Young.
Andrew holds an MBA from the London Business School, a BA in Economics and Finance from the University of Newcastle upon Tyne and an ACA qualification from the Institute of Chartered Accountants in England and Wales.
Thomas A. Moore
Tom Moore is the Chairman and CEO of LifeCuff Technologies, Inc. developing a non-invasive medical device that delivers a therapy shown to deliver very significant benefits to victims of ischemic diseases such as heart attack, stroke, and diabetes.
He served as Chairman and CEO of Advaxis, Inc. a publicly traded developer of cancer vaccines, from December, 2006 to September, 2013.
A graduate of Princeton University, Mr. Moore joined Procter & Gamble in 1973. During this period, he led the introductions of Tide Liquid, Pert Plus and Aleve. In 1992 he was appointed President of Procter & Gamble’s Health Care Products Worldwide and Group Vice President of the Procter & Gamble Company. In this role, he was responsible for over $3 billion of worldwide Over the Counter and Prescription drug sales in over one hundred countries and an R&D budget of over $200 million.
In 1996, Mr. Moore became CEO of the fastest growing company in the medical communications and consulting sector – privately held Nelson Communication, Inc. Over the next four years, revenues increased from $35,000,000 to $145,000,000, In January, 2001, Nelson was sold to the Publicis Groupe for $246 million.
From June 2002 to February 2004 Mr. Moore served as President, CEO of Biopure Corporation, a developer, manufacturer and marketer of oxygen therapeutics. Mr. Moore is a Board member for: Healogix, a pharmaceutical strategy and market research firm and Ectropy a direct marketing firm for major medical and cosmetic services. He was the lead investor in Motionpoint, a website translation firm.
Mr. Moore is a past board member of StoryCorps, Inc., the National Public Radio Foundation, the D&R Greenway Land Trust, past Chairman and President of the Cincinnati Ballet Company and has been a board member of the Fine Arts Institute of Cincinnati, the Alliance For a Drug Free Canada, the Mercy Hospital System of Southwest Ohio and the Miller Center for Public Affairs at The University of Virginia.
He resides in Philadelphia, Pennsylvania.
Diana (Didi) Scott has spent the majority of her career at Merck & Co. Inc. in a diversity of marketing roles, including marketing planning, marketing research and marketing promotion. Her experience in the pharmaceutical industry spans 28+ years as a Vice President in both US and global operations.
In addition to her experience in big pharma, Didi was part of a group of Merck executives appointed to design and implement a new joint venture pharmaceutical company, Astra Merck, focused on the marketing and sales of Astra-developed products. In addition to leading a variety of franchise teams responsible for the marketing and sales of Gastrointestinal, Cardiovascular and Infectious Disease products, Didi worked on the design and implementation of new marketing support organizations. Didi has also put her marketing expertise to work in the not-for-profit sector. For the last 10 years, she has been a member of the Board of Directors of Laurel House, a comprehensive domestic violence agency in Montgomery County, PA. For four of those years, she served as Co-President/President of the board, helping to lead the agency through a constantly changing and challenging funding environment.
Didi earned her MBA in Marketing from Temple University and BA in Fine Arts from Colgate University.
Bart has over 30 years of experience as a marketing research consultant, senior executive and leader. He has advised the world’s leading biopharmaceutical companies for more than 25 years.
Bart served as President of GfK Healthcare from 2005-2008. He was President of V2 from 2001 until it’s acquisition by GfK in 2005. Prior to that he was President of Migliara/Kaplan Associates.
Bart currently serves on the Board of Directors of the University of Georgia’s Market Research Institute. He is also a member of the Temple University Political Science Department Advisory Board. Bart previously served on the Board of Directors of NASDQ-listed American Pacific Corporation, a manufacturer of active pharmaceutical ingredients.
Bart holds a B.A. in Political Science from Temple University